Mainz Biomed N.V. Ordinary Shares (MYNZ)
Mainz Biomed N.V. is a biotechnology company focused on developing and commercializing innovative diagnostic solutions for early detection of cancer. The company specializes in non-invasive tests for gastrointestinal health, leveraging molecular biology and advanced technology to enhance early diagnosis and improve patient outcomes.
Company News
Mainz Biomed conducted a feasibility study on a non-invasive blood test for early pancreatic cancer detection, achieving 100% sensitivity and 95% specificity in identifying cancer and precancerous lesions across a 30-subject cohort.
Mainz Biomed shares jumped 16% in pre-market trading after the company announced submission for the FDA Breakthrough Device Designation for its next generation CRC screening test. Several other stocks also saw significant pre-market movement.
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 8% and 10.86%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
The molecular genetics diagnostic company announced the pricing of a follow-on stock offering.